MetaVia to Participate in the 9th Annual MASH-TAG 2025 Conference After Releasing Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH
MetaVia (Nasdaq: MTVA) announced its participation as a Sponsor and Exhibitor at the 9th Annual MASH-TAG 2025 Conference, scheduled for January 9-11 at the Chateaux Deer Valley in Park City, Utah. This announcement follows the company's recent disclosure of positive top-line 16-week results from their Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH). The company's management and clinical team will be present at the conference's Exhibit Hall to discuss the trial results.
MetaVia (Nasdaq: MTVA) ha annunciato la sua partecipazione come Sponsor ed Espositore alla 9ª Conferenza Annuale MASH-TAG 2025, in programma dal 9 all'11 gennaio presso il Chateaux Deer Valley a Park City, Utah. Questo annuncio segue la recente comunicazione da parte dell'azienda riguardo ai positivi risultati preliminari delle 16 settimane dal loro studio clinico di Fase 2a di DA-1241, un innovativo agonista del recettore G-Protein-Coupled Receptor 119 (GPR119), in pazienti con presunta steatoepatite associata a disfunzione metabolica (MASH). Il management e il team clinico dell'azienda saranno presenti nel Padiglione Espositivo della conferenza per discutere i risultati dello studio.
MetaVia (Nasdaq: MTVA) anunció su participación como Patrocinador y Expositor en la 9ª Conferencia Anual MASH-TAG 2025, programada del 9 al 11 de enero en el Chateaux Deer Valley en Park City, Utah. Este anuncio sigue a la reciente divulgación de resultados positivos de 16 semanas de su ensayo clínico de Fase 2a de DA-1241, un novedoso agonista del receptor G-Protein-Coupled Receptor 119 (GPR119), en pacientes con presunta esteatohepatitis asociada a disfunción metabólica (MASH). La gerencia y el equipo clínico de la empresa estarán presentes en el Salón de Exposición de la conferencia para discutir los resultados del ensayo.
MetaVia (Nasdaq: MTVA)는 유타주 파크 시티의 Chateaux Deer Valley에서 1월 9일부터 11일까지 예정된 MASH-TAG 2025 회의에서 후원사 및 전시업체로 참여할 것이라고 발표했습니다. 이번 발표는 회사가 추정된 대사 기능 장애 관련 지방간염(MASH) 환자를 대상으로 한 DA-1241의 2상 임상 시험에서 16주 동안 긍정적인 초기 결과를 공개한 것에 따른 것입니다. 회사의 경영진과 임상 팀은 회의의 전시 홀에 참석하여 시험 결과를 논의할 예정입니다.
MetaVia (Nasdaq: MTVA) a annoncé sa participation en tant que Sponsor et Exposant à la 9e Conférence Annuelle MASH-TAG 2025, prévue du 9 au 11 janvier au Chateaux Deer Valley à Park City, Utah. Cette annonce fait suite à la récente divulgation par l'entreprise de résultats positifs préliminaires de 16 semaines de leur essai clinique de Phase 2a sur DA-1241, un nouvel agoniste du récepteur couplé aux protéines G 119 (GPR119), chez des patients présentant une stéatohépatite associée à une dysfonction métabolique présumée (MASH). La direction de l'entreprise et l'équipe clinique seront présentes dans le hall d'exposition de la conférence pour discuter des résultats de l'essai.
MetaVia (Nasdaq: MTVA) gab seine Teilnahme als Sponsor und Aussteller an der 9. Jahrestagung MASH-TAG 2025 bekannt, die vom 9. bis 11. Januar im Chateaux Deer Valley in Park City, Utah, stattfindet. Diese Ankündigung folgt auf die kürzlich bekannt gegebenen positiven Ergebnisse der 16-wöchigen Phase-2a-Studie zu DA-1241, einem neuartigen Agonisten des G-Protein-gekoppelten Rezeptors 119 (GPR119), bei Patienten mit vermuteter metabolischer Dysfunktion-assoziierter Steatohepatitis (MASH). Das Management und das klinische Team des Unternehmens werden im Ausstellungsbereich der Konferenz anwesend sein, um die Studienergebnisse zu diskutieren.
- Positive top-line results achieved in Phase 2a trial of DA-1241
- Successfully completed 16-week clinical trial period
- None.
Insights
The Phase 2a trial results for DA-1241, while mentioned as "positive," lack important details about efficacy endpoints, safety data, or statistical significance. Without these specifics, it's impossible to evaluate the true clinical impact or market potential. The GPR119 agonist mechanism is interesting for MASH treatment, as it could potentially address both metabolic and inflammatory components of the disease, but the article provides no data to support this potential.
The conference participation, while providing a platform to present these results, is a routine business activity. The timing of the announcement, coming after top-line results, suggests this is more about visibility than material news. MASH-TAG is a respected industry event, but participation alone doesn't constitute market-moving information.
For investors, this announcement combines a marketing event with a reference to previously announced clinical data, neither of which provides new actionable information about the company's progress or valuation.
About MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control.
For more information, please visit www.metaviatx.com.
Contacts:
MetaVia
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@metaviatx.com
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/metavia-to-participate-in-the-9th-annual-mash-tag-2025-conference-after-releasing-positive-top-line-results-from-its-phase-2a-clinical-trial-of-da-1241-in-patients-with-presumed-mash-302335535.html
SOURCE MetaVia Inc.
FAQ
What were the results of MetaVia's (MTVA) Phase 2a trial for DA-1241?
When will MetaVia (MTVA) present at the MASH-TAG 2025 Conference?
What is the mechanism of action for MetaVia's (MTVA) DA-1241 drug?
What is MetaVia's (MTVA) role at the MASH-TAG 2025 Conference?
